abstract: The purpose of this study was to clarify the efficacy and safety of @entity1205 and @entity900 as second-line treatment for @entity1 with S-1 refractory advanced @entity356 . Between 1999 and 2006, 32 @entity1 received @entity1205 (60 mg/m  ) and @entity900 (60 mg/m  ) (Dp regimen) on day 1 every 3 weeks. This regimen was repeated at least three times at 3-week intervals until disease progression or unacceptable @entity137 was detected. The overall response rate was 21.9%. Seven @entity1 showed partial response, 17 showed stable disease and 8 showed disease progression. The median survival time was 12.3 months after the start of the first-line treatment. The median survival time and time to progression following the DP regimen was 7.8 months and 4.0 months, respectively. The major adverse effects were @entity1431 and neutropnea. Non-hematological @entity137 were generally mild to moderate and controllable. this study showed satisfactory therapeutic outcomes for @entity1 with @entity356 refractory to S- 1 chemotherapy.

title: Second-line @entity1205 plus XXXX for advanced @entity356 showing resistance to S-1.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']

answer: @entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']


abstract: The purpose of this study was to clarify the efficacy and safety of @entity1205 and @entity900 as second-line treatment for @entity1 with S-1 refractory advanced @entity356 . Between 1999 and 2006, 32 @entity1 received @entity1205 (60 mg/m  ) and @entity900 (60 mg/m  ) (Dp regimen) on day 1 every 3 weeks. This regimen was repeated at least three times at 3-week intervals until disease progression or unacceptable @entity137 was detected. The overall response rate was 21.9%. Seven @entity1 showed partial response, 17 showed stable disease and 8 showed disease progression. The median survival time was 12.3 months after the start of the first-line treatment. The median survival time and time to progression following the DP regimen was 7.8 months and 4.0 months, respectively. The major adverse effects were @entity1431 and neutropnea. Non-hematological @entity137 were generally mild to moderate and controllable. this study showed satisfactory therapeutic outcomes for @entity1 with @entity356 refractory to S- 1 chemotherapy.

title: Second-line @entity1205 plus @entity900 for advanced XXXX showing resistance to S-1.

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric cancer']


abstract: The purpose of this study was to clarify the efficacy and safety of @entity1205 and @entity900 as second-line treatment for @entity1 with S-1 refractory advanced @entity356 . Between 1999 and 2006, 32 @entity1 received @entity1205 (60 mg/m  ) and @entity900 (60 mg/m  ) (Dp regimen) on day 1 every 3 weeks. This regimen was repeated at least three times at 3-week intervals until disease progression or unacceptable @entity137 was detected. The overall response rate was 21.9%. Seven @entity1 showed partial response, 17 showed stable disease and 8 showed disease progression. The median survival time was 12.3 months after the start of the first-line treatment. The median survival time and time to progression following the DP regimen was 7.8 months and 4.0 months, respectively. The major adverse effects were @entity1431 and neutropnea. Non-hematological @entity137 were generally mild to moderate and controllable. this study showed satisfactory therapeutic outcomes for @entity1 with @entity356 refractory to S- 1 chemotherapy.

title: Second-line XXXX plus @entity900 for advanced @entity356 showing resistance to S-1.

answer: @entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']


abstract: @entity2206 ( @entity2207 ) is an environmental contaminant that causes adverse developmental effects in laboratory animals. To investigate the low-dose effects of @entity2207 on offspring, timed-pregnant @entity2659 @entity19 were gavage dosed with @entity2207 for all or half of gestation. In the full-gestation study, @entity19 were administered 0, 0.3, 1.0, and 3.0 mg @entity2207 /kg body weight (BW)/day from gestation days (GD) 1-17. In the late-gestation study, @entity19 were administered 0, 0.01, 0.1, and 1.0 mg @entity2207 /kg BW/day from GD 10-17. Exposure to @entity2207 significantly (p < 0.05) increased offspring relative liver weights in all treatment groups in the full-gestation study and in the 1.0 mg @entity2207 /kg group in the late-gestation study. In both studies, the offspring of all @entity2207 -treated dams exhibited significantly stunted mammary epithelial growth as assessed by developmental scoring. At postnatal day 21, mammary glands from the 1.0 mg/kg GD 10-17 group had significantly less longitudinal epithelial growth and fewer terminal end buds compared with controls (p < 0.05). Evaluation of internal dosimetry in offspring revealed that @entity2207 concentrations remained elevated in liver and serum for up to 6 weeks and that brain concentrations were low and undetectable after 4 weeks. These data indicate that @entity2207 -induced effects on mammary tissue (1) occur at lower doses than effects on liver weight in @entity2659 @entity19 , an observation that may be strain specific, and (2) persist until 12 weeks of age following full-gestational exposure. Due to the low-dose sensitivity of mammary glands to @entity2207 in @entity2659 @entity19 , a no observable adverse effect level for mammary developmental delays was not identified in these studies.

title: Prenatal @entity2206 exposure in XXXX @entity19 : low-dose developmental effects and internal dosimetry.

entities_list: @entity2206 :: ('MESH:C023036', 'Chemical') :: ['Perfluorooctanoic acid']

answer: @entity2659 :: (111334(Tax:10090),Gene) :: ['CD-1']


abstract: @entity2206 ( @entity2207 ) is an environmental contaminant that causes adverse developmental effects in laboratory animals. To investigate the low-dose effects of @entity2207 on offspring, timed-pregnant @entity2659 @entity19 were gavage dosed with @entity2207 for all or half of gestation. In the full-gestation study, @entity19 were administered 0, 0.3, 1.0, and 3.0 mg @entity2207 /kg body weight (BW)/day from gestation days (GD) 1-17. In the late-gestation study, @entity19 were administered 0, 0.01, 0.1, and 1.0 mg @entity2207 /kg BW/day from GD 10-17. Exposure to @entity2207 significantly (p < 0.05) increased offspring relative liver weights in all treatment groups in the full-gestation study and in the 1.0 mg @entity2207 /kg group in the late-gestation study. In both studies, the offspring of all @entity2207 -treated dams exhibited significantly stunted mammary epithelial growth as assessed by developmental scoring. At postnatal day 21, mammary glands from the 1.0 mg/kg GD 10-17 group had significantly less longitudinal epithelial growth and fewer terminal end buds compared with controls (p < 0.05). Evaluation of internal dosimetry in offspring revealed that @entity2207 concentrations remained elevated in liver and serum for up to 6 weeks and that brain concentrations were low and undetectable after 4 weeks. These data indicate that @entity2207 -induced effects on mammary tissue (1) occur at lower doses than effects on liver weight in @entity2659 @entity19 , an observation that may be strain specific, and (2) persist until 12 weeks of age following full-gestational exposure. Due to the low-dose sensitivity of mammary glands to @entity2207 in @entity2659 @entity19 , a no observable adverse effect level for mammary developmental delays was not identified in these studies.

title: Prenatal XXXX exposure in @entity2659 @entity19 : low-dose developmental effects and internal dosimetry.

answer: @entity2206 :: (MESH:C023036,Chemical) :: ['perfluorooctanoic acid']


abstract: @entity2206 ( @entity2207 ) is an environmental contaminant that causes adverse developmental effects in laboratory animals. To investigate the low-dose effects of @entity2207 on offspring, timed-pregnant @entity2659 @entity19 were gavage dosed with @entity2207 for all or half of gestation. In the full-gestation study, @entity19 were administered 0, 0.3, 1.0, and 3.0 mg @entity2207 /kg body weight (BW)/day from gestation days (GD) 1-17. In the late-gestation study, @entity19 were administered 0, 0.01, 0.1, and 1.0 mg @entity2207 /kg BW/day from GD 10-17. Exposure to @entity2207 significantly (p < 0.05) increased offspring relative liver weights in all treatment groups in the full-gestation study and in the 1.0 mg @entity2207 /kg group in the late-gestation study. In both studies, the offspring of all @entity2207 -treated dams exhibited significantly stunted mammary epithelial growth as assessed by developmental scoring. At postnatal day 21, mammary glands from the 1.0 mg/kg GD 10-17 group had significantly less longitudinal epithelial growth and fewer terminal end buds compared with controls (p < 0.05). Evaluation of internal dosimetry in offspring revealed that @entity2207 concentrations remained elevated in liver and serum for up to 6 weeks and that brain concentrations were low and undetectable after 4 weeks. These data indicate that @entity2207 -induced effects on mammary tissue (1) occur at lower doses than effects on liver weight in @entity2659 @entity19 , an observation that may be strain specific, and (2) persist until 12 weeks of age following full-gestational exposure. Due to the low-dose sensitivity of mammary glands to @entity2207 in @entity2659 @entity19 , a no observable adverse effect level for mammary developmental delays was not identified in these studies.

title: Prenatal @entity2206 exposure in @entity2659 XXXX : low-dose developmental effects and internal dosimetry.

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: Sixty-five cases of @entity5772 treated by surgery were reviewed. The types of operation included hemiglossectomy, subtotal and total glossectomy with or without hemimandibulectomy and laryngectomy. Simultaneous neck dissection was usually performed except for @entity1 who had radiotherapy and did not have clinical lymph node involvement. The hospital mortality and five-year survival rates were analysed for individual subgroups of @entity1 classified according to clinical and pathological features. The overall hospital mortality rate was 21.5 per cent. The size of the @entity5 and the presence of extension posteriorly, to the opposite side and to the floor of the mouth increased the mortality. Lesions situated on the dorsum fared worse than those at the edge or undersurface. Clinically and pathologically involved lymph nodes adversely affected the mortality. The more extensive the resection, the higher the mortality. Old age and previous failed radiotherapy also increased mortality. The overall five-year survival rate was 46 per cent. Long term survival was not so much affected by the size of the primary @entity5 and degree of local extension as was the hospital mortality. Clinical as well as pathological staging of regional lymph nodes were more important in influencing long term survival. Recurrence after radiotherapy had a worse prognosis than previously untreated @entity5 .

title: XXXX : factors affecting the results of surgical treatment.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour']

entities_list: @entity5772 :: ('MESH:D014062', 'Disease') :: ['carcinoma of the tongue']

answer: @entity5772 :: (MESH:D014062,Disease) :: ['Carcinoma of the tongue']


abstract: BACKGROUND: Analysis of @entity7110 ( @entity7110 ) produced during an immune response may be useful in elucidating some aspects of this process. Identification of antigens incorporated into @entity7110 provides information that may be helpful in developing diagnostic and treatment strategies for @entity792 , @entity281 , @entity5 , and transplantation therapy, and such information might be more relevant than information on free antigens. Because @entity7110 may contain many antigens, comprehensive identification and profiling of such antigens is more effective than immunoblotting detection. METHODS: We developed a novel proteomic strategy (immune complexome analysis) in which immune complexes (ICs) are separated from serum, digested directly with trypsin, and then subjected to nano-liquid chromatography-tandem mass spectrometry for identifying and profiling antigens in @entity7110 . We applied this strategy to the analysis of @entity7110 in 21 @entity309 ( @entity309 ) patients. Serum samples from 13 healthy donors and 8 @entity571 @entity1 were used as controls. RESULTS: @entity7110 containing @entity3499 ( @entity3499 ) and @entity18042 ( @entity18042 ) were found in the serum of 81% and 52% of @entity309 @entity1 , respectively, and in none of the controls. CONCLUSIONS: The ICs in the serum of a majority of the @entity309 @entity1 contained @entity3499 or @entity18042 , and these ICs may have potential as alternative biomarkers. Our technique for immune complexome analysis uses routine clinical samples, simple protocols, and widely available equipment. This method may be generally applicable to the study of the relationship between @entity7110 and certain diseases associated with the immune response in animals and @entity1 .

title: Immune complexome analysis of serum and its application in screening for immune complex antigens in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'humans']

entities_list: @entity7110 :: ('MESH:D007105', 'Disease') :: ['CICs', 'circulating immune complexes']

entities_list: @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune diseases']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']


abstract: OBJECTIVE: To determine the healing effect of topical becaplermin gel vs hydrogel dressing on @entity101 . DESIGN: Randomized, double-blind, parallel-assignment, controlled study. SETTING: Ambulatory or hospitalized @entity1 from 17 dermatology departments. @entity1 : Among 64 consecutive randomized @entity1 with 1 or more @entity101 who fulfilled all inclusion criteria, 59 received the allocated intervention, and findings were analyzed. INTERVENTION: Becaplermin gel ( @entity1 recombinant platelet-derived growth factor-BB, 0.1%, in hydrogel) or hydrogel dressing was applied, both in doses of 1 cm/cm(2), once daily for 8 weeks. Follow-up continued for 4 weeks beyond the final gel application. MAIN OUTCOME MEASURES: The primary end point was complete wound closure rate after 8 weeks of treatment. Secondary end points were percentages of @entity1 with complete wound closure at week 12; changed @entity1066 area after treatment vs baseline; and changed @entity1066 -related @entity158 and health-related quality of life during the study. RESULTS: Complete wound closure rates were comparable after 8 weeks for @entity35745 (5 of 28 @entity1 ) and hydrogel (3 of 31 @entity1 ) (8 percentage-point difference; 95% confidence interval, -10% to 26%). No statistically significant differences were observed between the 2 groups for percentages of complete closure at week 12, changed @entity1066 area at week 8, or changed @entity1066 -related @entity158 and quality of life during the study (P > .05 for all comparisons). CONCLUSIONS: Topical becaplermin gel is not superior to hydrogel dressing for @entity101 leg @entity1066 wound closure. Surgical management by grafting remains the most promising treatment strategy but requires further evaluation. Trial Registration clinicaltrials.gov Identifier: NCT00970697.

title: Topical treatment of XXXX with platelet-derived growth factor-BB: a randomized controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'human', 'PATIENTS']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive leg ulcers', 'hypertensive']

entities_list: @entity35745 :: ('MESH:C072194', 'Chemical') :: ['becaplermin']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertensive leg ulcers']


abstract: BACKGROUND: No studies document the incidence or results of @entity281 and patellar @entity397 after anterior cruciate ligament reconstruction with a contralateral patellar tendon autograft. PURPOSE: To determine the results of @entity1 who have @entity281 and patellar @entity397 after anterior cruciate ligament reconstruction with a patellar tendon autograft and compare the results between ipsilateral and contralateral grafts. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: The authors determined the incidence of @entity281 requiring surgical intervention and complete patellar @entity397 after surgery. Data were analyzed in 2 groups based on the graft source: ipsilateral (n = 2553) or contralateral (n = 2811). Data reviewed included range of motion, quadriceps strength, and subjective evaluations. RESULTS: Infections occurred in 9 ipsilateral @entity1 (0.35%) and 4 contralateral @entity1 (0.14%) (P = .12). At final follow-up, less than normal knee extension was found in 4 ipsilateral @entity1 and 1 contralateral @entity1 ; less than normal flexion was found in 4 ipsilateral @entity1 and 2 contralateral @entity1 . @entity397 occurred in 6 ipsilateral @entity1 (0.24%) and 7 contralateral @entity1 (0.25%) (P = .92). At 1 month after patellar tendon repair, mean motion (degree of hyperextension-degree short of 0   extension-degree of flexion) in the contralateral group was 5-0-137 in the reconstructed knee and 5-0-118 in the graft-donor knee, which was greater than 5-0-98 found in the ipsilateral group for the reconstructed knee (P < .05). The mean Noyes subjective score at a mean of 4 years postoperatively for the tendon-ruptured knee was 87 points in the ipsilateral group and 93 points in the contralateral group (P = .32), which is comparable with the published normative data for the Noyes score reporting a mean score of 93.6    8.3 points. CONCLUSION: There were no significant differences in the incidence of @entity281 or @entity397 between the ipsilateral and contralateral groups. @entity1 with complications after anterior cruciate ligament reconstruction with a patellar tendon autograft may have less difficulty obtaining full knee motion when the graft is harvested from the contralateral knee.

title: Infections and patellar XXXX after anterior cruciate ligament reconstruction: a comparison of ipsilateral and contralateral patellar tendon autografts.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['Patellar tendon ruptures', 'patellar tendon rupture', 'tendon ruptures']

answer: @entity397 :: (MESH:D012421,Disease) :: ['tendon ruptures']


abstract: OBJECTIVE: To identify age-related changes in @entity1 meibomian glands that may be associated with @entity409 ( @entity409 ). METHODS: Excess eyelid tissue from 36 @entity1 (age range, 18-95 years, 19 female, 17 male) who underwent canthoplasty procedures were used. Dermatologic history, age, and presence of @entity409 were recorded. Samples were frozen, sectioned, and stained with specific antibodies against @entity6864 ( @entity6864 ) to identify meibocyte differentiation, Ki67 nuclear antigen to identify cycling cells, and @entity1195 to identify inflammatory cell infiltration. RESULTS: Staining for @entity6864 showed cytoplasmic and nuclear localization in the 2 youngest subjects (ages, 18 and 44 years). Older individuals (>60 years) showed predominantly nuclear staining, with cytoplasmic staining limited to the basal acinar cells in 17 of 31 subjects. The number of Ki67 positively stained basal cells were significantly elevated in the younger compared with older subjects based on linear regression analysis (r(2) = 0.35; P < .001). There was also a significant correlation between MG expression grade and @entity1195 cell infiltration (r = 0.414; P = .05). CONCLUSIONS: These results indicate that aging @entity1 meibomian glands show decreased meibocyte differentiation and cell cycling that is associated with the development of @entity409 . Findings also suggest that altered @entity6864 signaling may lead to acinar @entity194 and development of an age-related hyposecretory @entity409 . CLINICAL RELEVANCE: @entity409 and evaporative @entity936 are common age-related @entity3066 . Understanding the underlying mechanism of @entity409 may lead to the development of novel therapeutic strategies to treat this disease.

title: Effects of age and dysfunction on XXXX meibomian glands.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['MGD', 'Meibomian gland dysfunction', 'meibomian gland dysfunction']

entities_list: @entity3066 :: ('MESH:D005141', 'Disease') :: ['eyelid disorders']

entities_list: @entity6864 :: ('5468', 'Gene') :: ['PPARy', 'peroxisome proliferator-activated receptor y']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVES: To demonstrate a rare but potential mechanism of @entity1688 in a @entity1 with fulminant @entity2506 complicated by severe intracranial @entity101 . DESIGN: Case report. SETTING: Intensive care unit. @entity1 : A 21-year-old @entity1 who presented with 3 days of @entity10 , combativeness, and @entity221 . INTERVENTION: Antibiotics and @entity230 were initiated after lumbar puncture yielded purulent cerebrospinal fluid and @entity328 . RESULTS: The @entity1 's course was complicated by severe @entity2657 necessitating intracranial pressure monitoring and intracranial pressure-targeted therapy. Within 5 days he developed @entity1688 and @entity4894 . Brain and cervical spine magnetic resonance imaging revealed patchy areas of T2 signal hyperintensity with associated @entity2287 enhancement in the superior cervical spinal cord, cerebellar tonsils, and medulla. CONCLUSIONS: @entity1688 secondary to tonsillar herniation in @entity693 is rare but should be considered in @entity1 with acute @entity1688 after treatment of @entity428 . Magnetic resonance imaging signal changes and @entity2287 enhancement may be demonstrated. Significant improvement of cord symptoms can be expected.

title: Cervicomedullary injury after XXXX with @entity2657 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'man', 'PATIENT']

entities_list: @entity1688 :: ('MESH:D011782', 'Disease') :: ['Quadriplegia', 'quadriparesis', 'quadriplegia']

entities_list: @entity2657 :: ('MESH:D001929', 'Disease') :: ['cerebral edema']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity4894 :: ('MESH:D019846', 'Disease') :: ['areflexia']

entities_list: @entity328 :: ('1313', 'Species') :: ['streptococcus pneumoniae']

entities_list: @entity428 :: ('MESH:D019586', 'Disease') :: ['increased intracranial pressure']

entities_list: @entity2506 :: ('MESH:D008586', 'Disease') :: ['pneumococcal meningitis']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['fulminant meningitis']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity2287 :: ('MESH:D005682', 'Chemical') :: ['gadolinium']

answer: @entity2506 :: (MESH:D008586,Disease) :: ['pneumococcal meningitis']


abstract: OBJECTIVES: To demonstrate a rare but potential mechanism of @entity1688 in a @entity1 with fulminant @entity2506 complicated by severe intracranial @entity101 . DESIGN: Case report. SETTING: Intensive care unit. @entity1 : A 21-year-old @entity1 who presented with 3 days of @entity10 , combativeness, and @entity221 . INTERVENTION: Antibiotics and @entity230 were initiated after lumbar puncture yielded purulent cerebrospinal fluid and @entity328 . RESULTS: The @entity1 's course was complicated by severe @entity2657 necessitating intracranial pressure monitoring and intracranial pressure-targeted therapy. Within 5 days he developed @entity1688 and @entity4894 . Brain and cervical spine magnetic resonance imaging revealed patchy areas of T2 signal hyperintensity with associated @entity2287 enhancement in the superior cervical spinal cord, cerebellar tonsils, and medulla. CONCLUSIONS: @entity1688 secondary to tonsillar herniation in @entity693 is rare but should be considered in @entity1 with acute @entity1688 after treatment of @entity428 . Magnetic resonance imaging signal changes and @entity2287 enhancement may be demonstrated. Significant improvement of cord symptoms can be expected.

title: Cervicomedullary injury after @entity2506 with XXXX .

answer: @entity2657 :: (MESH:D001929,Disease) :: ['brain edema']


abstract: BACKGROUND: The Work Limitations Questionnaire-25 (WLQ-25) and the Work Instability Scale for @entity309 (RA-WIS) have been used to measure at-work disability related to @entity85 . However, a recent systematic review has shown that important psychometric properties still needed to be evaluated. OBJECTIVE: The purpose of this study was to establish the validity and responsiveness of the WLQ-25 and RA-WIS in @entity1 with chronic work-related @entity851 . DESIGN: Two-hundred six @entity1 with chronic @entity851 who attended a specialty clinic operated by the Workplace Safety _ Insurance Board of Ontario were evaluated at their initial visit and 6 months later. METHODS: Questionnaires completed at each evaluation were: the WLQ-25, the RA-WIS, the QuickDASH, the @entity158 subscale of the Shoulder @entity158 and Disability Questionnaire, and the @entity1118 Grade Questionnaire. At the 6-month evaluation, @entity1 completed a global rating of change question. Known-group and construct convergent validity were assessed using analysis of variance and Pearson correlations, and standardized response means (SRMs) were used to assess responsiveness. @entity922 ( @entity922 ) also were determined. RESULTS: The WLQ-25 and RA-WIS had low to moderate correlations with @entity158 and disability scales (.28<r<.62) and discriminated among different functional categories (P<.001). For improved @entity1 , the WLQ-25 (SRM=0.65 for summed score, SRM=0.63 for index score) and the RA-WIS (SRM=0.66) demonstrated moderate responsiveness. The CID for improvement was estimated to be 13/100 points for the WLQ-25 summed score, 5/28.6 points for the WLQ-25 index score, and 4/23 points for the RA-WIS. LIMITATIONS: The external criterion of change was specific to change in @entity2045 and not to change in work ability or productivity. CONCLUSIONS: The WLQ-25 and RA-WIS provide different information from that provided by @entity158 and disability measures. They discriminate among functional outcome subgroups and detect improvement over time in @entity1 with chronic work-related @entity851 .

title: Validity and responsiveness of presenteeism scales in chronic work-related XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'people']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['upper-extremity disorders']

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['upper-extremity condition']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['musculoskeletal disorders']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['Chronic Pain']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['Rheumatoid Arthritis']

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['CIDs', 'Clinically important differences']

answer: @entity851 :: (MESH:D006130,Disease) :: ['upper-extremity disorders']


abstract: @entity3181 is characterized by @entity3181 . We describe a @entity1 with a huge caudate lobe of the liver due to @entity3181 . A 49-year-old @entity1 was referred to Nippon Medical School Hospital to receive treatment for enlarged @entity2312 . She had been followed up for @entity28406 with @entity409 for 7 years and had undergone surgery for @entity189 5 years earlier. Upper gastrointestinal endoscopy revealed @entity2312 without esophageal varices. Abdominal computed tomography revealed obstructions and scars of the right, middle, and left hepatic veins. The caudate lobe was enlarged, and the portal vein was displaced ventrally, without @entity715 . The drainage vein of the caudate lobe, the short hepatic vein on the left side of the inferior vena cava, was dilated. The portal vein and drainage vein of segment 6 were visualized and showed no @entity194 . Venography revealed no obstruction of the inferior vena cava. @entity3181 with @entity2312 was diagnosed on the basis of these findings. We performed balloon-occluded retrograde transvenous obliteration and partial @entity887 to treat the @entity2312 . The posttreatment course was uneventful, and the @entity1 was discharged 8 days after embolization. The @entity2312 shrank.

title: Huge caudate lobe of the liver due to XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patient']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['deformity of the liver']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['pharyngeal carcinoma']

entities_list: @entity28406 :: ('MESH:C537903', 'Disease') :: ['idiopathic portal hypertension']

entities_list: @entity887 :: ('MESH:D004617', 'Disease') :: ['splenic embolization']

entities_list: @entity3181 :: ('MESH:D006502', 'Disease') :: ['hepatic venous outflow obstruction', 'Budd-Chiari syndrome']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']

entities_list: @entity2312 :: ('MESH:D004932', 'Disease') :: ['gastric varices', 'solitary gastric varices']

answer: @entity3181 :: (MESH:D006502,Disease) :: ['Budd-Chiari syndrome']


abstract: INTRODUCTION: Osseointegrated bone-anchored hearing systems (BAHSs) are a useful tool in auditory rehabilitation for single-sided @entity2319 and conductive/mixed @entity393 . They rely on adequate osseointegration of @entity702 implants, which can be limited by @entity9332 . This study examines adult computed tomographic (CT) temporal bone normative data for @entity9332 in the areas commonly recommended for BAHS insertion and identifies hazards that may compromise the osseointegration process. METHODS: Prospective analysis of 100 consecutive adult helical CT scans. Calvarial thickness was measured in axial and coronal planes 5.5 cm posterior to the superior external auditory canal at 6 vertical points ( @entity30037 cm). Other parameters measured include temporal bone pneumatization and the presence of suture lines, bone marrow, and vascular structures. RESULTS: A total of 195 temporal bones were examined in 100 @entity1 . Mean @entity1 age was 60.9 years, of whom 54.4% were @entity1 and 45.6% were @entity1 . Mean @entity9332 was greatest at +1 cm above the @entity30037 level (6.3 mm) and thinnest at +4 cm (5.1 mm). Of temporal bones, 55% had at least 1 site thinner than 4 mm and 21% had at least 1 site thinner than 3 mm. Air cells and suture lines were more likely to be encountered within 2 cm above the @entity30037 level, and marrow space is more likely to be encountered 3 to 4 cm above the @entity30037 level. DISCUSSION: Selecting a position 3 to 4 cm above the level of the @entity30037 is more likely to result in dural exposure for a 3-mm BAHS abutment, especially in @entity1 . Selecting a position near the level of the @entity30037 provides thicker bone, but the surgeon is more likely to encounter suture line or enter mastoid air cells. Preoperative CT imaging may be a useful tool in evaluating @entity9332 and hazards when planning BAHS insertion in the adult population.

title: Computed tomographic analysis of outer XXXX for osseointegrated bone-anchored hearing system insertion.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men']

entities_list: @entity9332 :: ('MESH:C537963', 'Disease') :: ['calvarial thickness']

entities_list: @entity702 :: ('MESH:D014025', 'Chemical') :: ['titanium']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss']

answer: @entity9332 :: (MESH:C537963,Disease) :: ['calvarial thickness']


abstract: @entity13900 ) is a unique oncogenic virus with distinctive biological properties. @entity13900 is the only virus causing a naturally occurring @entity2 ( @entity420 , OPA) and possessing a major structural protein that functions as a dominant oncoprotein. @entity2 is the major cause of @entity204 among @entity5 @entity1 . OPA can be an extremely useful animal model in order to identify the cells originating @entity2220 and to study the early events of @entity105 . In this study, we demonstrated that @entity2220 in @entity742 originates from @entity281 and transformation of proliferating type 2 pneumocytes (termed here lung alveolar proliferating cells, LAPCs). We excluded that OPA originates from a bronchioalveolar stem cell, or from mature post-mitotic type 2 pneumocytes or from either proliferating or non-proliferating Clara cells. We show that young animals possess abundant LAPCs and are highly susceptible to @entity13900 @entity281 and transformation. On the contrary, healthy adult @entity742 , which are normally resistant to experimental OPA induction, exhibit a relatively low number of LAPCs and are resistant to @entity13900 @entity281 of the respiratory epithelium. Importantly, induction of @entity651 increased dramatically the number of LAPCs in adult @entity742 and rendered these animals fully susceptible to @entity13900 @entity281 and transformation. Furthermore, we show that @entity13900 preferentially infects actively dividing cell in vitro. Overall, our study provides unique insights into pulmonary biology and @entity105 and suggests that @entity13900 and its host have reached an evolutionary equilibrium in which productive @entity281 (and transformation) can occur only in cells that are scarce for most of the lifespan of the @entity742 . Our data also indicate that, at least in this model, @entity32 can predispose to @entity281 and @entity5 .

title: XXXX originates from retrovirus @entity281 of proliferating type 2 pneumocytes during pulmonary post-natal development or tissue repair.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['Lung cancer', 'lung cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['ovine pulmonary adenocarcinoma']

entities_list: @entity651 :: ('MESH:D055370', 'Disease') :: ['lung injury']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'retroviral infection']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis', 'pulmonary carcinogenesis']

entities_list: @entity13900 :: ('11746', 'Species') :: ['JSRV', 'Jaagsiekte sheep retrovirus (JSRV']

entities_list: @entity2220 :: ('MESH:C538231', 'Disease') :: ['lung adenocarcinoma']

answer: @entity2220 :: (MESH:C538231,Disease) :: ['Lung adenocarcinoma']


abstract: @entity13900 ) is a unique oncogenic virus with distinctive biological properties. @entity13900 is the only virus causing a naturally occurring @entity2 ( @entity420 , OPA) and possessing a major structural protein that functions as a dominant oncoprotein. @entity2 is the major cause of @entity204 among @entity5 @entity1 . OPA can be an extremely useful animal model in order to identify the cells originating @entity2220 and to study the early events of @entity105 . In this study, we demonstrated that @entity2220 in @entity742 originates from @entity281 and transformation of proliferating type 2 pneumocytes (termed here lung alveolar proliferating cells, LAPCs). We excluded that OPA originates from a bronchioalveolar stem cell, or from mature post-mitotic type 2 pneumocytes or from either proliferating or non-proliferating Clara cells. We show that young animals possess abundant LAPCs and are highly susceptible to @entity13900 @entity281 and transformation. On the contrary, healthy adult @entity742 , which are normally resistant to experimental OPA induction, exhibit a relatively low number of LAPCs and are resistant to @entity13900 @entity281 of the respiratory epithelium. Importantly, induction of @entity651 increased dramatically the number of LAPCs in adult @entity742 and rendered these animals fully susceptible to @entity13900 @entity281 and transformation. Furthermore, we show that @entity13900 preferentially infects actively dividing cell in vitro. Overall, our study provides unique insights into pulmonary biology and @entity105 and suggests that @entity13900 and its host have reached an evolutionary equilibrium in which productive @entity281 (and transformation) can occur only in cells that are scarce for most of the lifespan of the @entity742 . Our data also indicate that, at least in this model, @entity32 can predispose to @entity281 and @entity5 .

title: @entity2220 originates from retrovirus XXXX of proliferating type 2 pneumocytes during pulmonary post-natal development or tissue repair.

answer: @entity281 :: (MESH:D007239,Disease) :: ['infection']


abstract: @entity463 ( @entity463 ) is the most common and aggressive primary @entity1313 with very poor @entity1 median survival. To identify a microRNA (miRNA) expression signature that can predict @entity463 @entity1 survival, we analyzed the miRNA expression data of @entity463 @entity1 (n=222) derived from The @entity5 (TCGA) dataset. We divided the @entity1 randomly into training and testing sets with equal number in each group. We identified 10 significant miRNAs using Cox regression analysis on the training set and formulated a risk score based on the expression signature of these miRNAs that segregated the @entity1 into high and low risk groups with significantly different survival times (hazard ratio [HR]=2.4; 95% CI=1.4-3.8; p<0.0001). Of these 10 miRNAs, 7 were found to be risky miRNAs and 3 were found to be protective. This signature was independently validated in the testing set (HR=1.7; 95% CI=1.1-2.8; p=0.002). @entity463 @entity1 with high risk scores had overall poor survival compared to the @entity1 with low risk scores. Overall survival among the entire @entity1 set was 35.0% at 2 years, 21.5% at 3 years, 18.5% at 4 years and 11.8% at 5 years in the low risk group, versus 11.0%, 5.5%, 0.0 and 0.0% respectively in the high risk group (HR=2.0; 95% CI=1.4-2.8; p<0.0001). Cox multivariate analysis with @entity1 age as a covariate on the entire @entity1 set identified risk score based on the 10 miRNA expression signature to be an independent predictor of @entity1 survival (HR=1.120; 95% CI=1.04-1.20; p=0.003). Thus we have identified a miRNA expression signature that can predict @entity463 @entity1 survival. These findings may have implications in the understanding of gliomagenesis, development of targeted therapy and selection of high risk @entity5 @entity1 for adjuvant therapy.

title: A ten-microRNA expression signature predicts survival in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['GBM', 'Glioblastoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer Genome Atlas', 'cancer']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumor']

answer: @entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']


abstract: BACKGROUND: @entity1691 ( @entity1691 ) is one of the most common @entity627 with gender differences in prevalence and clinical presentation. This study aimed to examine whether such gender differences are correlated with cumulative healthcare utilization in Taiwan. METHODS: The National Health Insurance Research Database supplied claim records of one million individuals from 1996 to 2007. Selected cases included @entity1 aged >16 years. Certified rheumatologists diagnosed the @entity1 in three or more visits and gave prescriptions for @entity1691 . Multivariate adjusted logistic regression analyses were used to calculate the influence of gender on cumulative healthcare utilization associated with @entity1691 . RESULTS: The study included 228 @entity1 and 636 @entity1 . After adjustment for potential confounding factors, @entity1 had more cumulative outpatient visits associated with @entity1691 (odds ratio, 1.59; 95% confidence interval, 1.13 -2.23; p = 0.008). @entity1 also exhibited a trend for higher frequency of @entity1691 -related hospitalization (p = 0.054). CONCLUSION: @entity1 are more likely to have high cumulative @entity1691 -associated healthcare utilization than @entity1 . Further investigation of the causal factors is warranted.

title: Gender differences in XXXX -associated cumulative healthcare utilization: a population-based cohort study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Men', 'men']

entities_list: @entity1691 :: ('MESH:D013167', 'Disease') :: ['Ankylosing spondylitis', 'AS']

entities_list: @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic diseases']

answer: @entity1691 :: (MESH:D013167,Disease) :: ['ankylosing spondylitis']


abstract: Obesity can adversely affect @entity1 health, including fertility. While @entity28 can disturb the hormonal profile of the female organism and is associated with fertility loss, little is known about what effect male @entity28 has on fertility. The present study analysed sperm samples of 153 donors. The @entity1 were selected from couples attending an @entity249 clinic, who had tried for 12 months or more to achieve pregnancy without success. The age of the @entity1 under investigation was recorded, and their body mass index (BMI) was calculated. All semen samples were assessed for volume, concentration, motility and morphology. Sperm chromatin integrity was measured by sperm chromatin structure assay. Quality of sperm chromatin condensation was assessed by @entity11979 , @entity31470 and @entity28946 staining. We can conclude that the impact of elevated BMI on the parameters investigated (basic semen parameters, chromatin integrity and chromatin condensation) was not proven in this study. On the other hand, ejaculate quality appeared to be affected by ageing. The impact was reflected by chromatin integrity, which is a factor that can substantially affect fertility in @entity1 , rather than by basic sperm parameters.

title: Male XXXX and age in relationship to semen parameters and sperm chromatin integrity.

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity31470 :: ('MESH:C017006', 'Chemical') :: ['aniline blue']

entities_list: @entity11979 :: ('MESH:D014048', 'Chemical') :: ['toluidine blue']

entities_list: @entity28946 :: ('MESH:D014128', 'Chemical') :: ['chromomycin A3']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: We compared the tolerability and efficacy of @entity618 ( @entity2098 ) versus @entity618 (MPS) among renal transplant recipients on @entity1140 -based immunosuppression. The 105 @entity1 who underwent kidney transplantation between January 2002 and March 2008 and were treated with @entity134 , @entity1140 , and a @entity3442 compound were enrolled in the study. From @entity1 files we collected on demographics data, donors, immunosuppressive drug doses, biochemical and hematologic parameters, gastrointestinal and hematologic side effects, and kidney function. Fifty-six @entity1 were prescribed @entity2098 and 49 of them were taking MPS. Demographic parameters and pretransplantation dialysis duration were similar between the 2 groups. After the third month, the MPS dose was higher than that of @entity2098 . There were no clinically important differences between the 2 groups, regarding other immunosuppressive drug doses. Gastrointestinal side effects were similar: 42.4% in the @entity2098 versus 44.8% in the MPS group (P = .846). Six @entity1 in the @entity2098 group and 1 @entity1 in the MPS group underwent a switch of the @entity3442 therapy due to severe gastrointestinal side effects (P = .183). Biopsy-proven acute rejection was reported in 6 @entity1 on @entity2098 and 7 @entity1 on MPS therapy (P = .768). The log-rank test evaluating a 50% reduction in glomerular filtration rate (GFR) showed no significant difference between the 2 groups (P = .719). No deaths were recorded during the study period; there was only 1 graft loss, which occurred in the @entity2098 group. We did not observe a significant difference in tolerability and efficacy between the 2 widely used @entity3442 derivatives. Economic considerations can be an important factor when choosing the drug.

title: A comparison of @entity618 with @entity618 in renal transplant recipients on XXXX -based treatment.

entities_list: @entity3442 :: ('MESH:D009173', 'Chemical') :: ['mycophenolic acid']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate sodium', 'mycophenolate mofetil']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus']

answer: @entity1140 :: (MESH:D016559,Chemical) :: ['tacrolimus']


abstract: We compared the tolerability and efficacy of @entity618 ( @entity2098 ) versus @entity618 (MPS) among renal transplant recipients on @entity1140 -based immunosuppression. The 105 @entity1 who underwent kidney transplantation between January 2002 and March 2008 and were treated with @entity134 , @entity1140 , and a @entity3442 compound were enrolled in the study. From @entity1 files we collected on demographics data, donors, immunosuppressive drug doses, biochemical and hematologic parameters, gastrointestinal and hematologic side effects, and kidney function. Fifty-six @entity1 were prescribed @entity2098 and 49 of them were taking MPS. Demographic parameters and pretransplantation dialysis duration were similar between the 2 groups. After the third month, the MPS dose was higher than that of @entity2098 . There were no clinically important differences between the 2 groups, regarding other immunosuppressive drug doses. Gastrointestinal side effects were similar: 42.4% in the @entity2098 versus 44.8% in the MPS group (P = .846). Six @entity1 in the @entity2098 group and 1 @entity1 in the MPS group underwent a switch of the @entity3442 therapy due to severe gastrointestinal side effects (P = .183). Biopsy-proven acute rejection was reported in 6 @entity1 on @entity2098 and 7 @entity1 on MPS therapy (P = .768). The log-rank test evaluating a 50% reduction in glomerular filtration rate (GFR) showed no significant difference between the 2 groups (P = .719). No deaths were recorded during the study period; there was only 1 graft loss, which occurred in the @entity2098 group. We did not observe a significant difference in tolerability and efficacy between the 2 widely used @entity3442 derivatives. Economic considerations can be an important factor when choosing the drug.

title: A comparison of XXXX with @entity618 in renal transplant recipients on @entity1140 -based treatment.

answer: @entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate mofetil']


abstract: We compared the tolerability and efficacy of @entity618 ( @entity2098 ) versus @entity618 (MPS) among renal transplant recipients on @entity1140 -based immunosuppression. The 105 @entity1 who underwent kidney transplantation between January 2002 and March 2008 and were treated with @entity134 , @entity1140 , and a @entity3442 compound were enrolled in the study. From @entity1 files we collected on demographics data, donors, immunosuppressive drug doses, biochemical and hematologic parameters, gastrointestinal and hematologic side effects, and kidney function. Fifty-six @entity1 were prescribed @entity2098 and 49 of them were taking MPS. Demographic parameters and pretransplantation dialysis duration were similar between the 2 groups. After the third month, the MPS dose was higher than that of @entity2098 . There were no clinically important differences between the 2 groups, regarding other immunosuppressive drug doses. Gastrointestinal side effects were similar: 42.4% in the @entity2098 versus 44.8% in the MPS group (P = .846). Six @entity1 in the @entity2098 group and 1 @entity1 in the MPS group underwent a switch of the @entity3442 therapy due to severe gastrointestinal side effects (P = .183). Biopsy-proven acute rejection was reported in 6 @entity1 on @entity2098 and 7 @entity1 on MPS therapy (P = .768). The log-rank test evaluating a 50% reduction in glomerular filtration rate (GFR) showed no significant difference between the 2 groups (P = .719). No deaths were recorded during the study period; there was only 1 graft loss, which occurred in the @entity2098 group. We did not observe a significant difference in tolerability and efficacy between the 2 widely used @entity3442 derivatives. Economic considerations can be an important factor when choosing the drug.

title: A comparison of @entity618 with XXXX in renal transplant recipients on @entity1140 -based treatment.

answer: @entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate sodium']


abstract: OBJECTIVE: Between 25% and 30% of @entity1 and adolescents experience @entity25 . These disorders are complex phenotypes that are regulated by many genes, the environment, and gene-environment interactions. The objective of this study was to evaluate the contribution of genetic and environmental factors to @entity146 in early childhood and to contribute to the knowledge on appropriate therapeutic approaches, using a twin design. @entity1 AND METHODS: Data on sleeping behavior were collected from 314 18-month-old twin pairs (127 monozygotic and 187 dizygotic)using a parent-rated questionnaire. We used structural equation modeling to estimate genetic and environmental variance components for different @entity146 (cosleeping, sleep duration, and night awakenings). RESULTS: Shared environment explained almost all (98.3%) of the total variance in cosleeping. Sleep duration was substantially influenced by shared environmental factors (64.1% nocturnal sleep and 61.2% diurnal sleep), with a moderate contribution of additive genetic effects (30.8% and 36.3% for nocturnal and diurnal sleep, respectively). For nocturnal waking episodes, we found a shared environmental contribution of 63.2% and a heritability estimate of 35.3%. CONCLUSIONS: Most @entity25 during early childhood are explained by common shared environmental factors, and behavioral interventions adopted by parents and focused on modifying @entity146 could contribute to solving @entity25 in this age group. However, the influence of genetic factors should not be underestimated, and research in this area could clarify the physiologic architecture of sleeping and contribute to selecting appropriate personalized therapeutic approaches.

title: Genetic and environmental factors shape XXXX sleep patterns: a study of 18-month-old twins.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'PATIENTS']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disorders', 'sleep disturbances']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['sleep behavior', 'sleep behaviors']

answer: @entity1 :: (9606,Species) :: ['infant']


abstract: PURPOSE: @entity23902 inhibitors, such as @entity73058 , are in clinical development in combination with cytotoxic agents for the treatment of solid @entity5 , including @entity788 . To maximize the likelihood of their clinical success, it is essential to optimize drug scheduling as well as pharmacodynamic biomarkers in preclinical models. EXPERIMENTAL DESIGN: We tested multiple schedules of administration of @entity136 and @entity73058 on the survival of @entity788 cells. Potential pharmacodynamic biomarkers including pChk1, pChk2, pHistone H3, and @entity522 were evaluated in vitro, followed by assessment of promising candidate biomarkers in vivo. We then went on to determine the contributions of @entity4333 and DNA damage to the mechanism(s) of induction of the identified biomarker, pS345 @entity23902 . RESULTS: @entity73058 given during and after or after @entity136 administration produced maximum chemosensitization. In vivo, @entity73058 significantly inhibited the growth of @entity788 xenografts in response to @entity136 . Of the biomarkers assessed, pS345 @entity23902 was most consistently increased in response to @entity136 and @entity73058 in @entity5 and normal tissues (hair follicles). pS345 @entity23902 induction in response to @entity136 and @entity73058 occurred in the presence of @entity4333 inhibition and in association with elevated yH2AX, suggesting that DNA damage is an underlying mechanism. CONCLUSIONS: @entity73058 sensitizes @entity788 to @entity136 in association with induction of pS345 @entity23902 . Together these data support the clinical investigation of @entity73058 with @entity136 in @entity788 under a dosing schedule in which @entity136 is administered concurrent with or before @entity73058 and in conjunction with skin biopsies to measure pS345 @entity23902 .

title: Assessment of XXXX phosphorylation as a pharmacodynamic biomarker of @entity23902 inhibition.

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer cells and tumors', 'pancreatic cancer', 'pancreatic tumor', 'pancreatic cancers']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity23902 :: (1111,Gene) :: ['chk1']


abstract: PURPOSE: @entity23902 inhibitors, such as @entity73058 , are in clinical development in combination with cytotoxic agents for the treatment of solid @entity5 , including @entity788 . To maximize the likelihood of their clinical success, it is essential to optimize drug scheduling as well as pharmacodynamic biomarkers in preclinical models. EXPERIMENTAL DESIGN: We tested multiple schedules of administration of @entity136 and @entity73058 on the survival of @entity788 cells. Potential pharmacodynamic biomarkers including pChk1, pChk2, pHistone H3, and @entity522 were evaluated in vitro, followed by assessment of promising candidate biomarkers in vivo. We then went on to determine the contributions of @entity4333 and DNA damage to the mechanism(s) of induction of the identified biomarker, pS345 @entity23902 . RESULTS: @entity73058 given during and after or after @entity136 administration produced maximum chemosensitization. In vivo, @entity73058 significantly inhibited the growth of @entity788 xenografts in response to @entity136 . Of the biomarkers assessed, pS345 @entity23902 was most consistently increased in response to @entity136 and @entity73058 in @entity5 and normal tissues (hair follicles). pS345 @entity23902 induction in response to @entity136 and @entity73058 occurred in the presence of @entity4333 inhibition and in association with elevated yH2AX, suggesting that DNA damage is an underlying mechanism. CONCLUSIONS: @entity73058 sensitizes @entity788 to @entity136 in association with induction of pS345 @entity23902 . Together these data support the clinical investigation of @entity73058 with @entity136 in @entity788 under a dosing schedule in which @entity136 is administered concurrent with or before @entity73058 and in conjunction with skin biopsies to measure pS345 @entity23902 .

title: Assessment of @entity23902 phosphorylation as a pharmacodynamic biomarker of XXXX inhibition.

answer: @entity23902 :: (1111,Gene) :: ['chk1']


abstract: OBJECTIVES: We evaluated the results of the Turkish arm of the GOOD survey which investigated the cardiometabolic risk profile and the control of blood pressure (BP) of adult @entity101 outpatients in 12 countries across Europe. STUDY DESIGN: A total of 218 @entity101 @entity1 (139 females, 79 males; mean age 57.2  10.9 years) from @entity233 were included in this pan-European survey. Blood pressure control (defined as BP <140/90 mmHg for nondiabetics and <130/80 mmHg for @entity6 ) and cardiometabolic risk factors such as @entity6 , @entity209 , @entity28 , sedentary lifestyle, and @entity2299 were evaluated in accordance with the 2003 ESH/ESC guidelines on management of @entity101 . RESULTS: Control of BP was achieved in only 21.6% of the @entity1 diagnosed with @entity101 for a mean duration of 7.7  5.4 years. The mean systolic and diastolic BPs were 144  21 mmHg and 88  14 mmHg, respectively. The most frequent concomitant disease was @entity6 (66 @entity1 , 30.3%). @entity1 with @entity6 had a higher prevalence of @entity209 compared to nondiabetics (78.8% vs. 48%, p<0.01). The absence of BP control was more pronounced among @entity6 than in nondiabetics for systolic (77.3% vs. 63.8%) and diastolic (84.9% vs. 57.2%) pressures. Nearly half of the @entity101 @entity1 had @entity2299 , but only 35.8% of them were treated with lipid lowering drugs. CONCLUSION: Despite appropriate treatment, poor BP control in Turkish @entity101 @entity1 was associated with @entity209 , @entity6 , and undertreatment of @entity2299 . Therefore, more effective measures must be taken in the management of cardiovascular risk factors to improve BP control.

title: Global cardiometabolic risk profile in @entity1 with XXXX : results from the Turkish arm of the pan-European GOOD survey.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetics', 'diabetes', 'diabetes mellitus', 'type 2 diabetes mellitus']

entities_list: @entity2299 :: ('MESH:D050171', 'Disease') :: ['atherogenic dyslipidemia']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: OBJECTIVES: We evaluated the results of the Turkish arm of the GOOD survey which investigated the cardiometabolic risk profile and the control of blood pressure (BP) of adult @entity101 outpatients in 12 countries across Europe. STUDY DESIGN: A total of 218 @entity101 @entity1 (139 females, 79 males; mean age 57.2  10.9 years) from @entity233 were included in this pan-European survey. Blood pressure control (defined as BP <140/90 mmHg for nondiabetics and <130/80 mmHg for @entity6 ) and cardiometabolic risk factors such as @entity6 , @entity209 , @entity28 , sedentary lifestyle, and @entity2299 were evaluated in accordance with the 2003 ESH/ESC guidelines on management of @entity101 . RESULTS: Control of BP was achieved in only 21.6% of the @entity1 diagnosed with @entity101 for a mean duration of 7.7  5.4 years. The mean systolic and diastolic BPs were 144  21 mmHg and 88  14 mmHg, respectively. The most frequent concomitant disease was @entity6 (66 @entity1 , 30.3%). @entity1 with @entity6 had a higher prevalence of @entity209 compared to nondiabetics (78.8% vs. 48%, p<0.01). The absence of BP control was more pronounced among @entity6 than in nondiabetics for systolic (77.3% vs. 63.8%) and diastolic (84.9% vs. 57.2%) pressures. Nearly half of the @entity101 @entity1 had @entity2299 , but only 35.8% of them were treated with lipid lowering drugs. CONCLUSION: Despite appropriate treatment, poor BP control in Turkish @entity101 @entity1 was associated with @entity209 , @entity6 , and undertreatment of @entity2299 . Therefore, more effective measures must be taken in the management of cardiovascular risk factors to improve BP control.

title: Global cardiometabolic risk profile in XXXX with @entity101 : results from the Turkish arm of the pan-European GOOD survey.

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Approximately 4 to 34 percent of @entity1 born with neonatal @entity5300 do not recover spontaneously and require surgery. Despite the increasing availability of microsurgical nerve repair, the authors hypothesize that this condition remains undertreated and that uninsured @entity1 and @entity1 with public insurance are less likely to receive treatment than those with private insurance. METHODS: The authors used a national sample of inpatient hospital discharge data from the Healthcare Cost and Utilization Kids Inpatient Databases for the years 1997, 2000, 2003, and 2006. Relevant discharges were identified using the International Classification of Diseases, Ninth Revision diagnosis code 767.6 for neonatal @entity5300 and procedure codes relating to nerve surgery. Weighted frequencies were calculated to generate national estimates for neonatal @entity5300 births and nerve surgery procedures for these @entity1 . RESULTS: A total of 21,758 births with neonatal @entity5300 and 721 admissions for nerve surgery were identified. Over time, utilization of nerve surgery procedures has generally increased (1.1 percent in 1997 to 3.2 percent in 2006). Treatment with nerve surgery varied significantly according to insurance status-3.8 percent among private insurance discharges, 2.9 percent among Medicaid insurance discharges, and 0.7 percent among self-pay/uninsured records (p < 0.001). The mean age among nerve surgery @entity1 was 235    75 days, and the mean total charges associated with microsurgical intervention was  24,534     30,460. CONCLUSIONS: Over the past decade, approximately 3.3 percent of neonatal @entity5300 births have undergone some form of primary microsurgical nerve surgical intervention, which may reflect underutilization of these procedures and limited access to care. Insurance status plays a significant role in the use of nerve surgery procedures, as neonates without private insurance were less likely to receive nerve surgery procedures than those with private insurance.

title: A national study to evaluate trends in the utilization of nerve reconstruction for treatment of neonatal XXXX [outcomes article].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'infants']

entities_list: @entity5300 :: ('MESH:D020516', 'Disease') :: ['brachial plexus palsy']

answer: @entity5300 :: (MESH:D020516,Disease) :: ['brachial plexus palsy']


abstract: Allografts of the forearm are still uncommon in the field of composite tissue allograft transplantation. In November 2007, a right-hand allograft and a left-hand/full-length forearm allograft were transplanted in a 30-year-old @entity1 who lost both hands and the vision in his left eye due to an explosion. The @entity1 underwent alemtuzumab and @entity134 induction therapy. @entity1140 , @entity618 , and low doses of @entity230 were given to prevent rejection. The allografts were rejected 3 times, but these episodes were controlled successfully. The immunosuppressive regimen was switched from @entity1140 to @entity3446 because of increased serum @entity1011 . The left allograft showed a @entity1159 due to muscle @entity82 that was conjectured to be associated with a perioperative @entity63 and permitted only a Moberg-type key pinch. In contrast, an excellent grade of function was observed in the right allograft. The Disabilities of the Shoulder, Arm, and Hand score improved from 70.83 to 36.6 and intrinsic musculature returned to both allografts. The @entity1 was able to work 2 years after transplantation. This is the first report of an @entity63 related to the successful allotransplantation of a composite tissue.

title: Perioperative XXXX and fibrotic degeneration of muscle in a forearm allograft: functional follow-up at 32 months post transplantation.

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic injury']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil']

entities_list: @entity1159 :: ('MESH:D003286', 'Disease') :: ['flexion contracture']

entities_list: @entity1140 :: ('MESH:D016559', 'Chemical') :: ['Tacrolimus', 'tacrolimus']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

answer: @entity63 :: (MESH:D007511,Disease) :: ['ischemic injury']


abstract: BACKGROUND: @entity6583 is a disease caused by the oral ingestion of eggs from the @entity1 parasitic worm @entity8785 . Although drugs are available they are controversial because of the side effects and poor efficiency. An expressed sequence tag (EST) library is a method used to describe the gene expression profile and sequence of mRNA from a specific organism and stage. Such information can be used in order to find new targets for the development of drugs and to get a better understanding of the parasite biology. METHODS AND FINDINGS: Here an EST library consisting of 5760 sequences from the @entity1707 cysticerca stage has been constructed. In the library 1650 unique sequences were found and of these, 845 sequences (52%) were novel to @entity8785 and not identified within other EST libraries. Furthermore, 918 sequences (55%) were of unknown function. Amongst the 25 most frequently expressed sequences 6 had no relevant similarity to other sequences found in the Genbank NR DNA database. A prediction of putative signal peptides was also performed and 4 among the 25 were found to be predicted with a signal peptide. Proposed vaccine and diagnostic targets T24, Tsol18/HP6 and Tso31d could also be identified among the 25 most frequently expressed. CONCLUSIONS: An EST library has been produced from @entity1707 cysticerca and analyzed. More than half of the different ESTs sequenced contained a sequence with no suggested function and 845 novel EST sequences have been identified. The library increases the knowledge about what genes are expressed and to what level. It can also be used to study different areas of research such as drug and diagnostic development together with parasite fitness via e.g. immune modulation.

title: Analyses of an expressed sequence tag library from XXXX , Cysticerca.

entities_list: @entity6583 :: ('MESH:D020019', 'Disease') :: ['Neurocysticercosis']

entities_list: @entity8785 :: ('6204', 'Species') :: ['Taenia solium', 'T. solium']

answer: @entity8785 :: (6204,Species) :: ['Taenia solium']


abstract: OBJECTIVE: To describe a @entity1 with @entity1640 and mesencephalic presentation of a @entity15924 and @entity202 antibody-associated paraneoplastic @entity16 . DESIGN: Case report. SETTING: The Colorado Neurological Institute @entity717 Center in Englewood, Colorado, and the Mayo Clinic in Rochester, Minnesota. @entity1 : A 55-year-old @entity1 with a paraneoplastic @entity16 characterized by @entity735 movement @entity146 , @entity2724 , and a @entity7463 in the setting of @entity189 . INTERVENTION: Immunotherapy for paraneoplastic @entity16 , surgery and radiotherapy for @entity5 , and symptomatic treatment for @entity304 and @entity25 . MAIN OUTCOME MEASURES: Polysomnography, multiple sleep latency test, and neurological examination. RESULTS: The @entity5 was detected at a limited stage and treatable. After oncological therapy and immunotherapy, symptoms stabilized. Treatment with @entity2728 improved daytime somnolence. CONCLUSIONS: Rapid onset and progression of @entity51 may be a clue to paraneoplastic etiology. Early treatment of a limited stage @entity5 (with or without immunotherapy) may possibly slow progression of @entity16 . Symptomatic treatment may be beneficial.

title: @entity2724 , REM @entity146 , and supranuclear gaze palsy associated with @entity15924 and XXXX antibodies and @entity189 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'man', 'PATIENT']

entities_list: @entity304 :: ('MESH:D010302', 'Disease') :: ['parkinsonism']

entities_list: @entity1640 :: ('MESH:D007027', 'Disease') :: ['diencephalic']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['sleep behavior disorder']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disorder', 'neurological symptoms']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['tonsillar carcinoma']

entities_list: @entity735 :: ('MESH:D005124', 'Disease') :: ['rapid eye']

entities_list: @entity2724 :: ('MESH:D009290', 'Disease') :: ['narcolepsy']

entities_list: @entity2728 :: ('MESH:C048833', 'Chemical') :: ['modafinil']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['multifocal deficits']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['Movement Disorders']

entities_list: @entity7463 :: ('MESH:D013494', 'Disease') :: ['progressive supranuclear palsy-like syndrome']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disorders']

answer: @entity202 :: (10687,Gene) :: ['Ma2']


abstract: OBJECTIVE: To describe a @entity1 with @entity1640 and mesencephalic presentation of a @entity15924 and @entity202 antibody-associated paraneoplastic @entity16 . DESIGN: Case report. SETTING: The Colorado Neurological Institute @entity717 Center in Englewood, Colorado, and the Mayo Clinic in Rochester, Minnesota. @entity1 : A 55-year-old @entity1 with a paraneoplastic @entity16 characterized by @entity735 movement @entity146 , @entity2724 , and a @entity7463 in the setting of @entity189 . INTERVENTION: Immunotherapy for paraneoplastic @entity16 , surgery and radiotherapy for @entity5 , and symptomatic treatment for @entity304 and @entity25 . MAIN OUTCOME MEASURES: Polysomnography, multiple sleep latency test, and neurological examination. RESULTS: The @entity5 was detected at a limited stage and treatable. After oncological therapy and immunotherapy, symptoms stabilized. Treatment with @entity2728 improved daytime somnolence. CONCLUSIONS: Rapid onset and progression of @entity51 may be a clue to paraneoplastic etiology. Early treatment of a limited stage @entity5 (with or without immunotherapy) may possibly slow progression of @entity16 . Symptomatic treatment may be beneficial.

title: @entity2724 , REM @entity146 , and supranuclear gaze palsy associated with XXXX and @entity202 antibodies and @entity189 .

answer: @entity15924 :: (9240,Gene) :: ['Ma1']


abstract: OBJECTIVE: To describe a @entity1 with @entity1640 and mesencephalic presentation of a @entity15924 and @entity202 antibody-associated paraneoplastic @entity16 . DESIGN: Case report. SETTING: The Colorado Neurological Institute @entity717 Center in Englewood, Colorado, and the Mayo Clinic in Rochester, Minnesota. @entity1 : A 55-year-old @entity1 with a paraneoplastic @entity16 characterized by @entity735 movement @entity146 , @entity2724 , and a @entity7463 in the setting of @entity189 . INTERVENTION: Immunotherapy for paraneoplastic @entity16 , surgery and radiotherapy for @entity5 , and symptomatic treatment for @entity304 and @entity25 . MAIN OUTCOME MEASURES: Polysomnography, multiple sleep latency test, and neurological examination. RESULTS: The @entity5 was detected at a limited stage and treatable. After oncological therapy and immunotherapy, symptoms stabilized. Treatment with @entity2728 improved daytime somnolence. CONCLUSIONS: Rapid onset and progression of @entity51 may be a clue to paraneoplastic etiology. Early treatment of a limited stage @entity5 (with or without immunotherapy) may possibly slow progression of @entity16 . Symptomatic treatment may be beneficial.

title: XXXX , REM @entity146 , and supranuclear gaze palsy associated with @entity15924 and @entity202 antibodies and @entity189 .

answer: @entity2724 :: (MESH:D009290,Disease) :: ['Narcolepsy']


abstract: OBJECTIVE: To describe a @entity1 with @entity1640 and mesencephalic presentation of a @entity15924 and @entity202 antibody-associated paraneoplastic @entity16 . DESIGN: Case report. SETTING: The Colorado Neurological Institute @entity717 Center in Englewood, Colorado, and the Mayo Clinic in Rochester, Minnesota. @entity1 : A 55-year-old @entity1 with a paraneoplastic @entity16 characterized by @entity735 movement @entity146 , @entity2724 , and a @entity7463 in the setting of @entity189 . INTERVENTION: Immunotherapy for paraneoplastic @entity16 , surgery and radiotherapy for @entity5 , and symptomatic treatment for @entity304 and @entity25 . MAIN OUTCOME MEASURES: Polysomnography, multiple sleep latency test, and neurological examination. RESULTS: The @entity5 was detected at a limited stage and treatable. After oncological therapy and immunotherapy, symptoms stabilized. Treatment with @entity2728 improved daytime somnolence. CONCLUSIONS: Rapid onset and progression of @entity51 may be a clue to paraneoplastic etiology. Early treatment of a limited stage @entity5 (with or without immunotherapy) may possibly slow progression of @entity16 . Symptomatic treatment may be beneficial.

title: @entity2724 , REM @entity146 , and supranuclear gaze palsy associated with @entity15924 and @entity202 antibodies and XXXX .

answer: @entity189 :: (MESH:D002277,Disease) :: ['tonsillar carcinoma']


abstract: OBJECTIVE: To describe a @entity1 with @entity1640 and mesencephalic presentation of a @entity15924 and @entity202 antibody-associated paraneoplastic @entity16 . DESIGN: Case report. SETTING: The Colorado Neurological Institute @entity717 Center in Englewood, Colorado, and the Mayo Clinic in Rochester, Minnesota. @entity1 : A 55-year-old @entity1 with a paraneoplastic @entity16 characterized by @entity735 movement @entity146 , @entity2724 , and a @entity7463 in the setting of @entity189 . INTERVENTION: Immunotherapy for paraneoplastic @entity16 , surgery and radiotherapy for @entity5 , and symptomatic treatment for @entity304 and @entity25 . MAIN OUTCOME MEASURES: Polysomnography, multiple sleep latency test, and neurological examination. RESULTS: The @entity5 was detected at a limited stage and treatable. After oncological therapy and immunotherapy, symptoms stabilized. Treatment with @entity2728 improved daytime somnolence. CONCLUSIONS: Rapid onset and progression of @entity51 may be a clue to paraneoplastic etiology. Early treatment of a limited stage @entity5 (with or without immunotherapy) may possibly slow progression of @entity16 . Symptomatic treatment may be beneficial.

title: @entity2724 , REM XXXX , and supranuclear gaze palsy associated with @entity15924 and @entity202 antibodies and @entity189 .

answer: @entity146 :: (MESH:D001523,Disease) :: ['sleep behavior disorder']


abstract: @entity460 controls an array of key events in keratinocytes and epidermis: localized changes in @entity141 concentrations and their regulation are therefore especially important to assess when observing epidermal barrier homeostasis and repair, neonatal barrier establishment, in differentiation, signaling, cell adhesion, and in various pathological states. Yet, tissue- and cellular @entity141 concentrations in physiologic and diseased states are only partially known, and difficult to measure. Prior observations on the @entity141 distribution in skin were based on @entity141 precipitation followed by electron microscopy, or proton-induced X-ray emission. Neither cellular and/or subcellular localization could be determined through these approaches. In cells in vitro, fluorescent dyes have been used extensively for ratiometric measurements of static and dynamic @entity141 concentrations, also assessing organelle @entity141 concentrations. For lack of better methods, these findings together build the basis for the current view of the role of @entity141 in epidermis, their limitations notwithstanding. Here we report a method using @entity460 Green 5N as the @entity460 sensor and the phasor-plot approach to separate raw lifetime components. Thus, fluorescence lifetime imaging (FLIM) enables us to quantitatively assess and visualize dynamic changes of @entity141 at light-microscopic resolution in ex vivo biopsies of unfixed epidermis, in close to in vivo conditions. Comparing undisturbed epidermis with epidermis following a barrier insult revealed major shifts, and more importantly, a mobilization of high amounts of @entity141 shortly following barrier disruption, from intracellular stores. These results partially contradict the conventional view, where barrier insults abrogate a @entity141 gradient towards the stratum granulosum. @entity141 FLIM overcomes prior limitations in the observation of epidermal @entity141 dynamics, and will allow further insights into basic epidermal physiology.

title: Major translocation of XXXX upon epidermal barrier insult: imaging and quantification via FLIM/Fourier vector analysis.

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium', 'Calcium']

answer: @entity460 :: (MESH:D002118,Chemical) :: ['calcium']


abstract: OBJECTIVES: @entity12040 ( @entity12040 ) may be associated with @entity29 ( @entity29 ). As there is such an overlap and since both diseases show @entity75 we reasoned similar biological pathways might be implicated in both conditions. Therefore, we investigated the prevalence of anti- @entity375 cerevisiae (ASCA) and anti-neutrophil cytoplasmic (ANCA) antibodies - serological markers for @entity29 -among @entity1 with @entity12040 . METHODS: Thirty-two @entity1 with @entity12040 , 21 with @entity30 ( @entity30 ), 17 with @entity31 ( @entity31 ) and 34 healthy controls were studied. Among 32 @entity1 with @entity12040 , 2 had @entity30 and one had @entity31 concomitantly. ASCA Ig A and Ig G antibodies were analyzed using a commercial ELISA kit. Immune fluorescence analysis (IFA) was used to assess the presence of ANCA antibodies. RESULTS: Only @entity1 with @entity30 had significantly higher levels of both ASCA Ig A and Ig G, compared to @entity1 with @entity12040 and healthy controls. Similarly, the frequency of ASCA positive @entity1 was higher only among @entity1 with @entity30 . ASCA Ig A and Ig G antibodies were found in 16 % (5/32) of @entity1 with @entity12040 . Among 3 @entity1 , in whom @entity12040 and @entity29 co-existed, only one (one with @entity30 ) had positive ASCA Ig G and A antibodies. The p-ANCA antibodies were present among @entity1 with @entity31 (35 %) and @entity30 (10 %). CONCLUSION: ASCA positivity in @entity12040 was similar to that found in @entity31 and healthy controls. No ANCA antibodies were detected among @entity1 with @entity12040 .

title: Anti- XXXX cerevisiae (ASCA) and anti-neutrophil cytoplasmic (ANCA) antibodies are not increased in @entity12040 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['granulomatous histopathological lesions']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD']

entities_list: @entity12040 :: ('MESH:D013625', 'Disease') :: ['TA', 'Takayasu arteritis']

entities_list: @entity375 :: ('4932', 'Species') :: ['Saccharomyces']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's disease"]

answer: @entity375 :: (4932,Species) :: ['Saccharomyces']


abstract: OBJECTIVES: @entity12040 ( @entity12040 ) may be associated with @entity29 ( @entity29 ). As there is such an overlap and since both diseases show @entity75 we reasoned similar biological pathways might be implicated in both conditions. Therefore, we investigated the prevalence of anti- @entity375 cerevisiae (ASCA) and anti-neutrophil cytoplasmic (ANCA) antibodies - serological markers for @entity29 -among @entity1 with @entity12040 . METHODS: Thirty-two @entity1 with @entity12040 , 21 with @entity30 ( @entity30 ), 17 with @entity31 ( @entity31 ) and 34 healthy controls were studied. Among 32 @entity1 with @entity12040 , 2 had @entity30 and one had @entity31 concomitantly. ASCA Ig A and Ig G antibodies were analyzed using a commercial ELISA kit. Immune fluorescence analysis (IFA) was used to assess the presence of ANCA antibodies. RESULTS: Only @entity1 with @entity30 had significantly higher levels of both ASCA Ig A and Ig G, compared to @entity1 with @entity12040 and healthy controls. Similarly, the frequency of ASCA positive @entity1 was higher only among @entity1 with @entity30 . ASCA Ig A and Ig G antibodies were found in 16 % (5/32) of @entity1 with @entity12040 . Among 3 @entity1 , in whom @entity12040 and @entity29 co-existed, only one (one with @entity30 ) had positive ASCA Ig G and A antibodies. The p-ANCA antibodies were present among @entity1 with @entity31 (35 %) and @entity30 (10 %). CONCLUSION: ASCA positivity in @entity12040 was similar to that found in @entity31 and healthy controls. No ANCA antibodies were detected among @entity1 with @entity12040 .

title: Anti- @entity375 cerevisiae (ASCA) and anti-neutrophil cytoplasmic (ANCA) antibodies are not increased in XXXX .

answer: @entity12040 :: (MESH:D013625,Disease) :: ['Takayasu arteritis']


abstract: INTRODUCTION: Since June 2008, Portuguese rheumatologists have been collecting on a routine basis, data into the nationwide Reuma.pt, the @entity627 Portuguese Register from the Portuguese Society of Rheumatology ( @entity29552 ), which includes @entity627 @entity1 ( @entity309 - @entity309 , @entity1691 - @entity5427 , @entity5144 - PsA and @entity4932 ) receiving biological therapies or @entity1 receiving synthetic disease modifying anti- @entity627 drugs (DMARDs). The aim of this publication is to describe the structure of Reuma.pt and the population registered since June 2008. METHODS: Demographic and anthropometric data, life style habits, work status, co-morbidities, disease activity and functional assessment scores, previous and current therapies, adverse events codified by the Medical Dictionary for Regulatory Activities (MedDRA), reasons for discontinuation and laboratory measurements are registered at each visit. The platform is based on a structured electronic medical record linked to a SQL Server database. All Rheumatology Departments assigned to the Portuguese National Health Service (n=21), 2 Military Hospitals (Lisboa and Porto), 1 public-private Institution and 6 private centers adhered to the Register. Until now, 18 centers have entered data into Reuma.pt. RESULTS: By January 2011, 3438 @entity1 and 16130 visits had been registered. 2162 (63%) were @entity309 @entity1 , 700 of them treated with biological agents and 1462 with synthetic DMARDs. From the 515 (15%) @entity5427 @entity1 , 297 were medicated with biological and 218 with non-biological therapies. 293 (8%) were PsA @entity1 , 151 treated with biological drugs and 142 with other treatment strategies. 368 (11%) had the diagnosis of JIA, 68 were under biological treatment and 300 were managed with other treatment options. The register also includes 100 (3%) @entity1 with other @entity627 , submitted to treatments that required hospital day care infusions including 18 exposed to biological therapies. CONCLUSIONS: Registers are crucial to ensure correct clinical use, adequate assessment of post-marketing biological therapies' efficacy and safety, thus contributing for a better cost-benefit ratio. Reuma.pt, is a powerful and accurate tool to answer to these unmet needs. It presents a national coverage of the rheumatology centers and constitutes an invaluable resource for scientific research and to improve @entity627 @entity1 care.

title: Reuma.pt - the XXXX portuguese register.

entities_list: @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic', 'Rheumatic Diseases', 'rheumatic diseases']

entities_list: @entity5144 :: ('MESH:D015535', 'Disease') :: ['psoriatic arthritis']

entities_list: @entity4932 :: ('MESH:D001171', 'Disease') :: ['juvenile idiopathic arthritis - JIA']

entities_list: @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

answer: @entity627 :: (MESH:D012216,Disease) :: ['rheumatic diseases']


abstract: Although the @entity4840 locomotor system has been shown to differ from @entity1 , characteristics of @entity4840 entheses, the skeletal attachments for muscles, tendons, ligaments and joint capsules, have never been specifically investigated. Here, we analyse lower limb entheses of the Krapina @entity4840 bones (Croatia, 130,000 BP) with the aim of determining how they compare with modern @entity1 , using a standard developed by our research group for describing modern @entity1 entheseal variability. The entheses examined are those of the gluteus maximus, iliopsoas and vastus medialis on the femur, the quadriceps @entity924 , and soleus on the tibia. For the entheses showing a different morphological pattern from @entity1 , we discuss the possibility of recognising genetic versus environmental causes. Our results indicate that only the gluteus maximus enthesis (the gluteal tuberosity), falls out of the modern @entity1 range of variation. It displays morphological features that could imply histological differences from modern @entity1 , in particular the presence of fibrocartilage. In both @entity1 and the Krapina @entity4840 , the morphological pattern of this enthesis is the same in adult and immature femurs. These results can be interpreted in light of genetic differences between the two hominins. The possibility of functional adaptations to higher levels of mechanical load during life in the @entity4840 seems less likely. The particular morphology and large dimensions of the Krapina enthesis, and perhaps its fibrocartilaginous nature, could have been selected for in association with other pelvic and lower limb characteristics, even if genetic drift cannot be ruled out.

title: Lower limb entheseal morphology in the XXXX Krapina population (Croatia, 130,000 BP).

entities_list: @entity1 :: ('9606', 'Species') :: ['Homo sapiens', 'humans', 'human', 'H. sapiens']

entities_list: @entity924 :: ('MESH:D052256', 'Disease') :: ['tendon on the patella']

entities_list: @entity4840 :: ('63221', 'Species') :: ['Neandertal', 'Neandertals']

answer: @entity4840 :: (63221,Species) :: ['Neandertal']


abstract: BACKGROUND: The effects of right ventricular (RV) pacing on left ventricular (LV) diastolic function are unknown. This study aimed to test the hypothesis that right ventricular (RV) pacing is associated with LV @entity67 and impairment of LV torsion in @entity1 and young adults with @entity6015 . METHODS: Eighteen @entity1 aged 20    7 years and 12 healthy controls aged 19    7 years were studied. Transmitral and mitral annular diastolic velocities and global longitudinal diastolic strain rate were determined and compared between the 2 groups. Parameters of LV torsion including peak systolic basal and @entity717 , and systolic twisting and diastolic untwisting velocities were further determined by speckle tracking echocardiography. In 12 @entity1 , these parameters were compared before and after interruption of RV pacing. RESULTS: Compared with controls, @entity1 had significantly lower mitral early diastolic annular velocity (p=0.007), LV global diastolic strain rate (p<0.001), basal (p<0.001) and apical (p=0.002) rotations, peak systolic torsion (p<0.001), and peak systolic twisting velocities (p=0.009). In @entity1 , the peak diastolic untwisting velocity correlated with peak systolic torsion (r=0.64, p=0.004) and peak systolic twisting velocity (r=0.74, p<0.001). No significant improvement in LV diastolic function or torsion was observed during pacing interruption (all p>0.05). CONCLUSION: Right ventricular pacing in childhood is associated with LV @entity67 and @entity1002 , which do not improve with pacing interruption.

title: Left ventricular torsional mechanics and diastolic function in XXXX with right ventricular pacing.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['apical rotations']

entities_list: @entity67 :: ('MESH:D018754', 'Disease') :: ['diastolic dysfunction']

entities_list: @entity6015 :: ('MESH:C535758', 'Disease') :: ['congenital heart block']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['impaired LV torsion']

answer: @entity6015 :: (MESH:C535758,Disease) :: ['congenital heart block']


abstract: Previous studies have demonstrated @entity1944 in rectal biopsy specimens from 2 to 7 percent of heterosexual and 36 percent of homosexual @entity1 , but the role of @entity1944 in the pathogenesis of @entity1944 remains unclear. To assess the clinical, histologic, and microbiologic correlates of @entity1944 in a high-risk group, rectal biopsy specimens from 130 homosexual @entity1 , 92 percent of whom had intestinal symptoms, were evaluated. All @entity1 were extensively evaluated for rectal and enteric pathogens. Intestinal spirochetosis was identified in rectal biopsy specimens from 39 (30 percent) @entity1 ; 15 percent of biopsy specimens revealed @entity1944 on @entity1710 and @entity1711 plus alcian blue staining, and positive results were found in 30 percent on @entity575 staining. No rectal biopsy specimens from 79 control @entity1 with a variety of gastrointestinal symptoms demonstrated evidence of spirochetosis on @entity1710 and @entity1711 , alcian blue, or @entity575 staining (p less than 0.0001). Fifty-six percent of rectal biopsy specimens from @entity1 with @entity1944 were normal, and no specific histologic abnormality was correlated with @entity1944 . There were no differences in the presence of or type of intestinal symptoms, sigmoidoscopic appearance of the mucosa, type of sexual practice, or prior antibiotic use in @entity1 with and without spirochetosis. Other intestinal pathogens were frequent in both groups, and only @entity2954 was significantly associated with @entity1944 . It is concluded that homosexual @entity1 with intestinal symptoms have an increased prevalence of spirochetosis, often in association with @entity6368 . Independent association of spirochetosis with clinical or histologic findings could not be demonstrated.

title: Intestinal spirochetosis in homosexual XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity1944 :: ('MESH:D007410', 'Disease') :: ['intestinal disease', 'intestinal spirochetosis']

entities_list: @entity2954 :: ('MESH:D006069', 'Disease') :: ['rectal gonorrhea']

entities_list: @entity6368 :: ('485', 'Species') :: ['Neisseria gonorrhoeae']

entities_list: @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin']

answer: @entity1 :: (9606,Species) :: ['men']


abstract: BACKGROUND: Sleep disturbance may affect smoking cessation efforts. We describe sleep changes across three months among @entity1 in a smoking cessation program and tested whether @entity25 at baseline and 1 month post-quit attempt predicted smoking status at three months. METHODS: @entity1 (N=322) were @entity1 in a randomized, clinical trial for smoking cessation. Sleep disturbances, as well as, @entity22 , drowsiness, and sleep quality were evaluated prior to and during three months of cessation treatment. Repeated measures mixed models evaluated change in sleep over time by smoking outcome status. Logistic regression analyses determined whether @entity25 at baseline and 1 month post-quit were associated with smoking status at 3 months. RESULTS: Sleep disturbances were reported by more than 25% of @entity1 . Drowsiness, @entity22 , and sleep quality changed over time. However, contrary to our hypotheses, none of the sleep variables at either baseline or 1 month post-quit attempt was associated with relapse (p's>.05). CONCLUSIONS: Although mild to severe drowsiness was reported by more @entity1 who relapsed than those who remained abstinent, none of the @entity25 predicted smoking relapse. Given high rates of @entity25 among @entity1 smokers, better prospective evaluations of the relationship of @entity25 to smoking cessation treatment outcome are needed.

title: Subjective XXXX during a smoking cessation program: associations with relapse.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Participants']

entities_list: @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep disturbance symptoms', 'sleep disturbances']

entities_list: @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia']

answer: @entity25 :: (MESH:D012893,Disease) :: ['sleep disturbance']


abstract: The accurate prediction of individual outcomes after @entity302 surgery represents a key challenge facing clinicians. It requires a precise understanding of surgical candidacy and the optimal timing of surgery to maximize a range of outcomes, including medical, psychosocial, cognitive, and @entity146 outcomes. We promote careful consideration of how @entity302 has affected an individual's developmental trajectory as key to constructing more differentiated profiles of postsurgical risk or resilience across multiple outcome measures. This life span approach conceives surgery as a crucial "turning point" in an individual's development from which varied outcome trajectories may follow. This helps clinicians understand the expectations @entity1 and families bring to surgery, and emphasizes the interplay of factors that determine a @entity1 's outcome. It also promotes comprehensive, longitudinal assessment of outcome using data analytical techniques that capture individual differences and identify subgroups with similar trajectories. An ongoing challenge facing clinicians is the development of an outcome classification system that incorporates outcomes other than @entity410 . We illustrate two emerging areas of research shaping how we define surgical candidacy and predict outcome: (1) using cortico-cortical evoked potentials to identify pathways of @entity410 propagation and cortico-cortical networks mediating cortical functions, and (2) predicting @entity308 using a model that incorporates psychosocial and neurobiological factors. The latter research points to the importance of routine follow-up and postoperative psychosocial rehabilitation, particularly in @entity1 deemed at "high risk" for poor outcomes so that early treatment interventions can be implemented. Significantly more research is needed to characterize those @entity1 with poor outcomes who may require re-surgery.

title: Current challenges in the practice of XXXX surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['postoperative depression']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: @entity6884 in @entity1641 is a repetitive behavior pattern which may involve the activation of both narcotic receptors and @entity935 receptors in the CNS. @entity6884 frequency, determined in 7 nontreated @entity1641 under controlled conditions, was usually linear for many hours and ranged from 0.3 to 14.9 bites/min. Intravenous or IM injections of narcotic antagonists decreased these rates to almost zero by about 20 minutes after the injection was given. The duration of the response to a single injection ranged from 20 minutes for @entity1510 to 4 hours or more for @entity33479 and @entity16889 . Effective doses were 0.02 to 0.04 mg of @entity1510 /kg, 0.04 mg of @entity836 /kg, 0.08 mg of @entity33479 /kg, and 0.02 to 0.03 mg of @entity16889 /kg. @entity6884 could be prevented completely for up to a week by continuous infusion of 5 to 10 mg of @entity33479 /hr. @entity6884 resumed when the infusion was discontinued, and plasma @entity33479 concentrations decreased to below 5 ng/ml. Doses of @entity33479 as large as 0.4 mg/kg, IV, produced only minor side effects. These side effects included some passage of semifluid fecal material, intermittent penile relaxation, and mild sedation. Treated @entity1641 responded normally to external stimuli, retained their appetites, and performed appropriately when ridden. Sedation wore off during the course of prolonged infusions. Narcotic antagonists may provide a novel and effective treatment of @entity146 .

title: Investigation into the use of narcotic antagonists in the treatment of a stereotypic behavior pattern (crib-biting) in the XXXX .

entities_list: @entity16889 :: ('MESH:D004174', 'Chemical') :: ['diprenorphine']

entities_list: @entity836 :: ('MESH:D009271', 'Chemical') :: ['naltrexone']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['stereotypic behavior disorders']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity1510 :: ('MESH:D009270', 'Chemical') :: ['naloxone']

entities_list: @entity6884 :: ('MESH:D013398', 'Disease') :: ['Crib-biting']

entities_list: @entity33479 :: ('MESH:C038981', 'Chemical') :: ['nalmefene']

answer: @entity1641 :: (9796,Species) :: ['horse']